Summary
Signal counts
Assets tracked: 39
Watchlist assets: 31
Registry stop assets: 13
Sponsor overview
National Cancer Institute (NCI)
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07572123 | https://clinicaltrials.gov/study/NCT03284385 | https://clinicaltrials.gov/study/NCT01776008 | https://clinicaltrials.gov/study/NCT03587311 | https://clinicaltrials.gov/study/NCT01648348 | https://clinicaltrials.gov/study/NCT00089154 | https://clinicaltrials.gov/study/NCT06325683 | https://clinicaltrials.gov/study/NCT06820957 | https://clinicaltrials.gov/study/NCT05669664 | https://clinicaltrials.gov/study/NCT06390839 | https://clinicaltrials.gov/study/NCT05490771 | https://clinicaltrials.gov/study/NCT06126276 | https://clinicaltrials.gov/study/NCT01116648 | https://clinicaltrials.gov/study/NCT06390852 | https://clinicaltrials.gov/study/NCT04577755 | https://clinicaltrials.gov/study/NCT06311214 | https://clinicaltrials.gov/study/NCT01896999 | https://clinicaltrials.gov/study/NCT03468985 | https://clinicaltrials.gov/study/NCT00245063 | https://clinicaltrials.gov/study/NCT05295589 | https://clinicaltrials.gov/study/NCT07673341 | https://clinicaltrials.gov/study/NCT00019604 | https://clinicaltrials.gov/study/NCT04762888 | https://clinicaltrials.gov/study/NCT00303836 | https://clinicaltrials.gov/study/NCT02414945 | https://clinicaltrials.gov/study/NCT00958854 | https://clinicaltrials.gov/study/NCT05600686 | https://clinicaltrials.gov/study/NCT03041701 | https://clinicaltrials.gov/study/NCT00570401 | https://clinicaltrials.gov/study/NCT00742625 | https://clinicaltrials.gov/study/NCT00019890 | https://clinicaltrials.gov/study/NCT01849250 | https://clinicaltrials.gov/study/NCT00023998 | https://clinicaltrials.gov/study/NCT00902577 | https://clinicaltrials.gov/study/NCT01120275 | https://clinicaltrials.gov/study/NCT00666588 | https://clinicaltrials.gov/study/NCT02019693 | https://clinicaltrials.gov/study/NCT00182767 | https://clinicaltrials.gov/study/NCT00087139 | https://clinicaltrials.gov/study/NCT00924066 | https://clinicaltrials.gov/study/NCT00114283 | https://clinicaltrials.gov/study/NCT00005942 | https://clinicaltrials.gov/study/NCT01078441 | https://clinicaltrials.gov/study/NCT01415765 | https://clinicaltrials.gov/study/NCT00019929 | https://clinicaltrials.gov/study/NCT00079131 | https://clinicaltrials.gov/study/NCT03698994 | https://clinicaltrials.gov/study/NCT00040755 | https://clinicaltrials.gov/study/NCT00087373 | https://clinicaltrials.gov/study/NCT00026143 | https://clinicaltrials.gov/study/NCT00098813 | https://clinicaltrials.gov/study/NCT00513435 | https://clinicaltrials.gov/study/NCT03165721 | https://clinicaltrials.gov/study/NCT00841204 | https://clinicaltrials.gov/study/NCT03190967 | https://clinicaltrials.gov/study/NCT00126607 | https://clinicaltrials.gov/study/NCT00478140 | https://clinicaltrials.gov/study/NCT00450255
Assets
Linked programs
- 3-Dimensional Conformal Radiation Therapy: Operational Burden Signal (2/5)
- Adavosertib: Watchlist Signal (2/5)
- Akt Inhibitor MK2206: Registry Stop Signal (4/5)
- Anetumab Ravtansine: Watchlist Signal (2/5)
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105: Watchlist Signal (2/5)
- apolizumab: Results Not Found Signal (2/5)
- Biopsy Procedure: Registry Stop Signal (4/5)
- Cabozantinib: Watchlist Signal (2/5)
- cediranib maleate: Low Signal (1/5)
- Computed Tomography: Registry Stop Signal (5/5)
- cyclophosphamide: Registry Stop Signal (5/5)
- Dasatinib: Registry Stop Signal (4/5)
- daunorubicin hydrochloride: Low Signal (1/5)
- dendritic cell-gp100-MART-1 antigen vaccine: Results Not Found Signal (2/5)
- Docosahexaenoic Acid: Low Signal (1/5)
- doxorubicin hydrochloride: Results Not Found Signal (2/5)
- FMISO: Watchlist Signal (2/5)
- gamma-secretase/Notch signalling pathway inhibitor RO4929097: Registry Stop Signal (4/5)
- idarubicin: Low Signal (1/5)
- INC280: Watchlist Signal (2/5)
- ixabepilone: Low Signal (1/5)
- Ixempra (Ixabepilone (BMS-247550) ): Registry Stop Signal (4/5)
- lapatinib ditosylate: Results Not Found Signal (2/5)
- liposomal daunorubicin citrate: Results Not Found Signal (2/5)
- liposomal doxorubicin: Registry Stop Signal (4/5)
- MLN4924: Registry Stop Signal (4/5)
- mutant p53 peptide pulsed dendritic cell vaccine: Results Not Found Signal (2/5)
- oblimersen sodium: Results Not Found Signal (2/5)
- Pharmacokinetic Study: Operational Burden Signal (3/5)
- rebimastat: Results Not Found Signal (2/5)
- recombinant fowlpox-TRICOM vaccine: Registry Stop Signal (4/5)
- recombinant interleukin-12: Results Not Found Signal (3/5)
- romidepsin: Low Signal (1/5)
- saracatinib: Watchlist Signal (2/5)
- SGI-110 (guadecitabine): Registry Stop Signal (4/5)
- sulindac: Low Signal (1/5)
- T-DM1: Registry Stop Signal (4/5)
- trastuzumab: Registry Stop Signal (4/5)
- ziv-aflibercept: Low Signal (1/5)